DDInter1268 DDInter1435
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Muromonab
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Natalizumab may lead to a major life threatening interaction when taken with Muromonab